Skip to content

Oruka Therapeutics, Inc. ORKA Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss

Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss at other companies

Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position, accumulated loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position, accumulated loss?
Oruka Therapeutics, Inc. (ORKA) reported debt securities, available-for-sale, unrealized loss position, accumulated loss of $553K in Q1 2026.
How has Oruka Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position, accumulated loss changed year-over-year?
Oruka Therapeutics, Inc.'s debt securities, available-for-sale, unrealized loss position, accumulated loss increased by 1102.2% year-over-year, from $46K to $553K.